We conducted a comprehensive evidence‐based review on the epidemiology and current standard of care of gastroschisis management as well as the pathophysiology, rationale and feasibility of fetal therapy as a viable alternative. Gastroschisis is a periumbilical abdominal wall defect characterized by abdominal viscera herniation in utero. It affects 4 in 10 000 live births, but the prevalence has steadily increased in recent years. Gastroschisis is typically diagnosed on routine second‐trimester ultrasound. The overall prognosis is favorable, but complex gastroschisis, which accounts for about 10% to 15% of cases, is associated with a higher mortality, significant disease burden and higher healthcare costs due to long‐ and short‐term complications. The current standard of care has yet to be established but generally involves continued fetal surveillance and multidisciplinary perinatal care. Postnatal surgical repair is achieved with primary closure, staged silo closure or sutureless repair. Experimental animal studies have demonstrated the feasibility of in utero closure, antiinflammatory therapy and prenatal regenerative therapy. However, reports of early preterm delivery and amnioinfusion trials have failed to show any benefit in humans. Further experimental studies and human trials are necessary to demonstrate the potential benefit of fetal therapy in gastroschisis.

中文翻译：

---

胎儿干预在腹裂治疗中是否有作用？– 更新的综合评论

我们对腹裂治疗的流行病学和当前护理标准以及胎儿治疗作为可行替代方案的病理生理学、基本原理和可行性进行了全面的循证审查。腹裂是一种脐周腹壁缺损，其特征是子宫内的腹腔内脏突出。它影响每 10 000 个活产婴儿中的 4 个，但近年来患病率稳步上升。腹裂通常通过常规孕中期超声诊断。总体预后良好，但复杂性胃劈裂症（约占病例的 10% 至 15%）与较高的死亡率、显着的疾病负担和因长期和短期并发症导致的较高医疗费用相关。目前的护理标准尚未建立，但通常涉及持续的胎儿监测和多学科围产期护理。产后手术修复是通过初步闭合、分阶段的筒仓闭合或无缝缝合来实现的。实验动物研究证明了子宫内闭合、抗炎疗法和产前再生疗法的可行性。然而，早期早产和羊膜腔输注试验的报告未能显示对人类有任何益处。需要进一步的实验研究和人体试验来证明胎儿治疗腹裂的潜在益处。抗炎治疗和产前再生治疗。然而，早期早产和羊膜腔输注试验的报告未能显示对人类有任何益处。需要进一步的实验研究和人体试验来证明胎儿治疗腹裂的潜在益处。抗炎治疗和产前再生治疗。然而，早期早产和羊膜腔输注试验的报告未能显示对人类有任何益处。需要进一步的实验研究和人体试验来证明胎儿治疗腹裂的潜在益处。